On the Record · Universe Pharmaceuticals
Universe Pharmaceuticals acquisitions, on the record
The businesses Universe Pharmaceuticals bought and sold, as its annual reports describe them, with the cash it reported paying for acquisitions each year and every deal filing since 2016.
Deals its annual reports describe
| Business | Deal | When | Value |
|---|---|---|---|
Mr. Xibo Liu (equity transfer)Word for word“Based on contract terms, the Company prepaid RMB 25 million (approximately $ 3.4 million) within three (3) business days upon signing the letter of intent.” 20-F for 2023 | agreed acquisition | — | RMB 25 million (approximately $ 3.4 million) |
Yunnan Faxi (51% ownership)Word for word“On December 20, 2024, the equity transfer contract to transfer 51 % ownership in Yunnan Faxi was terminated due to unsatisfactory performance of Yunnan Faxi.” 20-F for 2024 | agreed acquisition | December 20, 2024 | — |
Read from Universe Pharmaceuticals’s annual reports (20-F for 2025, 20-F for 2024, 20-F for 2023) and the financial data it files with the SEC, as of 2026-01-29. Every quotation is word for word from the filing linked beside it; how these pages are built and checked. The full record is in its company data sheet.